Limitations to the development of Milan model 1b analytical performance specifications
Open Access
- 11 May 2026
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract
A widely accepted approach to setting Analytical Performance Specifications (APS) in laboratory medicine is the Milan models. Milan model 1b is an approach where APS are developed based on patient classification, or clinical decision-making, noting that these factors link to the probability of patient outcomes. This paper describes limitations that should be considered for any APS derived using model 1b, based on any available information from model 2 (biological variation), and model 3 (state of the art). It is also proposed that ”state of the art”, when defined as being tests which are routinely available, influences studies based on clinical surveys as this the background used by doctors to develop their clinical experience, as well as the ability for the APS to be put into routine use. Additionally, when ”state of the art” is defined as the method used in an outcome study, this becomes a reference where such studies cannot support a smaller assay precision, as the assay performance is only one aspect of the variation in the links between laboratory results and clinical findings. Model 1b studies remain a key approach to assigning clinical meaning to assay performance, however outcomes of these studies need to be taken with awareness of relevant limitations.Keywords
This publication has 19 references indexed in Scilit:
- Verifying measurements on Siemens Atellica® instruments using clinically acceptable analytical performance specificationsScandinavian Journal of Clinical and Laboratory Investigation, 2023
- The risk of clinical misinterpretation of HbA1c: Modelling the impact of biological variation and analytical performance on HbA1c used for diagnosis and monitoring of diabetesClinica Chimica Acta, 2023
- Establishing Pragmatic Analytical Performance Specifications for Blood Beta-Hydroxybutyrate TestingClinical Chemistry, 2023
- Clinical decision limits as criteria for setting analytical performance specifications for laboratory testsClinica Chimica Acta, 2023
- Variation in the hemoglobin glycation indexJournal of Diabetes and its Complications, 2022
- Biological variation: Understanding why it is so important?Practical Laboratory Medicine, 2021
- Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ TransplantationClinical Pharmacokinetics, 2020
- Analytical performance specifications based on how clinicians use laboratory tests. Experiences from a post-analytical external quality assessment programmeClinical Chemistry and Laboratory Medicine (CCLM), 2015
- Postanalytical External Quality Assessment of Blood Glucose and Hemoglobin A1c: An International SurveyClinical Chemistry, 2005
- Establishing a practical blood platelet threshold to avoid reporting spurious potassium results due to thrombocytosisAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2005